ArticleTropical diseases, travel medicine and vaccines2025
Imported plasmodium ovale malaria from Côte d'Ivoire: a case report.
Article in Tropical diseases, travel medicine and vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a significant global health issue, with an estimated 263 million cases and 597,000 deaths reported in 2023. Plasmodium ovale, although less common than P. falciparum and P. vivax, presents diagnostic challenges due to its morphological resemblance to P. vivax and its ability to form latent liver-stage hypnozoites, leading to delayed relapses. CASE PRESENTATION: This case report describes a 29-year-old male who presented with fever, chills, and myalgia upon returning to Bogotá, Colombia, after a three-month stay in Côte d'Ivoire, Africa. Initial microscopy misidentified the parasite as P. falciparum, leading to diagnostic uncertainty. Polymerase chain reaction (PCR) confirmed P. ovale infection, emphasizing the critical role of molecular diagnostics in differentiating malaria species. The patient was treated with chloroquine and primaquine for radical cure. Initially, the patient received artemether-lumefantrine empirically. Once the diagnosis of P. ovale was confirmed, he was switched to chloroquine followed by primaquine (15 mg base daily for 28 days) as radical cure. G6PD testing was not available in our setting, but the patient was monitored clinically and tolerated the medication without adverse effects.
conclusionsGiven that P. ovale is not endemic to Colombia, increased awareness among clinicians is necessary for accurate diagnosis and management of imported malaria cases. Enhanced surveillance and advanced diagnostic techniques are essential to prevent misdiagnosis and ensure appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.